AFP-specific T cell receptors with fine-tuning affinity induce durable tumor remission in mice and acquire pan-HLA-A∗02 recognition
Molecular Therapy · 2026-05 · 34 (5) · 2666-2677
DOI: 10.1016/j.ymthe.2026.01.026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2026-05. Verfasst von Chen-Song Huang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pancreato-Biliary Surgery, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China. Hauptthemen laut MEDLINE: alpha-Fetoproteins, Receptors, Antigen, T-Cell, HLA-A2 Antigen, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
T cell receptor-engineered T cell (TCR-T cell) therapies enable targeting of intracellular antigens presented by HLA molecules, addressing the limitations of solid tumors lacking surface antigens. We developed a novel alpha-fetoprotein (AFP)-specific TCR-T cell for hepatocellular carcinoma. Starting from a previously cloned AFP-specific TCR (A01) restricted by HLA-A∗02:03, we enhanced its affinity through structure-guided optimization. A single amino acid substitution in the CDR3 region of the TCR Vβ chain significantly enhanced the antigen-specific activity. This modified TCR (A01-m14) triggered robust responses in both CD4+ and CD8+ TCR-T cells, demonstrating potent efficacy against patient-derived organoids and in murine models. Notably, CD4+ and CD8+ TCR-T cells acted synergistically to sustain antitumor effects. A01-m14 TCR exhibited a favorable safety profile with no detectable off-target reactivity against the human proteome or unrelated HLA molecules. The further engineered TCR (A01-m58) was able to recognize most HLA-A∗02 subtypes, significantly expanding the eligible patient population. Meanwhile, the pan-A∗02-TCR-T cells also showed enhanced cytokine production, superior tumor cell killing, and achieved complete tumor eradication in murine models. This study developed an AFP-specific TCR-T cell with fine-tuning affinity, demonstrating remarkable preclinical efficacy and safety, alongside a sequence-optimized version with pan-HLA-A∗02 applicability, offering broader patient access and therapeutic versatility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pancreato-Biliary Surgery, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China.
- HRYZ Biotech Co., Guangzhou 510525, China.
- Key Laboratory of Stem Cells and Tissue Engineering, Ministry of Education, Sun Yat-sen University, Guangzhou 510080, China.
- HRYZ Biotech Co., Guangzhou 510525, China. Electronic address: chujunjun@gmail.com.
- HRYZ Biotech Co., Guangzhou 510525, China. Electronic address: hanyy@thyx.com.
Förderung
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Huang, C. S., Du, J., Li, J., Guo, Y. H., Yan, Q., Wu, S., Chen, X., Leong, T. F., Chen, S. Y., Zheng, A. D., Ou, S., Ma, M., Yang, C., Zhang, L., Zhou, X., Chu, J., & Han, Y. (2026). AFP-specific T cell receptors with fine-tuning affinity induce durable tumor remission in mice and acquire pan-HLA-A∗02 recognition. Molecular Therapy, 34(5), 2666-2677. https://doi.org/10.1016/j.ymthe.2026.01.026
Vancouver
Huang CS, Du J, Li J, Guo YH, Yan Q, Wu S, et al. AFP-specific T cell receptors with fine-tuning affinity induce durable tumor remission in mice and acquire pan-HLA-A∗02 recognition. Molecular Therapy. 2026;34(5):2666-2677. doi:10.1016/j.ymthe.2026.01.026
BibTeX
@article{Huang2026,
author = {Huang, Chen-Song and Du, Jiajia and Li, Jun and Guo, Ya-Hao and Yan, Qingjia and Wu, Shifan and Chen, Xihe and Leong, Tein Foong and Chen, Si-Yun and Zheng, An-Da and Ou, Shudan and Ma, Minjun and Yang, Chunguang and Zhang, Lulu and Zhou, Xiangjun and Chu, Junjun and Han, Yanyan},
title = {AFP-specific T cell receptors with fine-tuning affinity induce durable tumor remission in mice and acquire pan-HLA-A∗02 recognition},
journal = {Molecular Therapy},
year = {2026},
volume = {34},
number = {5},
pages = {2666--2677},
doi = {10.1016/j.ymthe.2026.01.026}
}
EUVIMED